Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
July 22, 2021 at 10:56 AM EDT
Biogen Inc posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship product, Tecfidera, a multiple sclerosis drug.
